Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

or it had a different mechanism of action. “There’s a lot of hype and excitement around GLP-1 and like medications,” Youssef. “And the thing I want to see is long-term safety data.

New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready – – Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in ...

Looking to avoid a repeat of the shortages that plagued Mounjaro and Zepbound during their initial rollouts, Eli Lilly is building supply of its oral GLP-1 contender ... in on the action, too.

Why would this be the case? The first reason is because the mechanism of action [MOA] of using a GLP-1 Receptor Agonist to help obesity patients lose weight is already established. Not only that ...